Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)

Merck Sharp & Dohme LLC4,266 enrolled

Overview

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

4,266

Conditions

Osteoporosis

Interventions

Disease Management AssessmentBEHAVIORAL

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months). Exclusion Criteria: * Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.

Outcomes

Primary Outcomes

A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.

Secondary Outcomes

BMD testing, osteoporosis medication prescriptions, fracture

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.